Novel agents in classical Hodgkin lymphoma

Leukemia & Lymphoma ◽

10.1080/10428194.2017.1300898 ◽

2017 ◽

Vol 58 (10) ◽

pp. 2275-2286 ◽

Author(s):

Sven Borchmann ◽

Bastian von Tresckow

Keyword(s):

Hodgkin Lymphoma ◽

Novel Agents ◽

Classical Hodgkin Lymphoma

Download Full-text

Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents

Leukemia & Lymphoma ◽

10.1080/10428194.2021.2002322 ◽

2021 ◽

pp. 1-8

Author(s):

Harsh Shah ◽

Hyejeong Jang ◽

Paramveer Singh ◽

Jorgena Kosti ◽

Andrew Kin ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Novel Agents ◽

Classical Hodgkin Lymphoma

Download Full-text

Review for "Rescue of chemorefractory classical Hodgkin lymphoma with Nivolumab and autologous stem‐cell transplantation: real‐life experience"

10.1002/hon.2796/v2/review1 ◽

2020 ◽

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Autologous Stem Cell Transplantation ◽

Life Experience ◽

Real Life ◽

Classical Hodgkin Lymphoma

Download Full-text

Decision letter for "Rescue of chemorefractory classical Hodgkin lymphoma with Nivolumab and autologous stem‐cell transplantation: real‐life experience"

10.1002/hon.2796/v2/decision1 ◽

2020 ◽

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Autologous Stem Cell Transplantation ◽

Life Experience ◽

Real Life ◽

Classical Hodgkin Lymphoma

Download Full-text

Decision letter for "Low‐dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: experience in a resource‐constrained setting"

10.1002/hon.2787/v2/decision1 ◽

2020 ◽

Keyword(s):

Hodgkin Lymphoma ◽

Low Dose ◽

Classical Hodgkin Lymphoma ◽

Resource Constrained

Download Full-text

Decision letter for "Low‐dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: experience in a resource‐constrained setting"

10.1002/hon.2787/v1/decision1 ◽

2020 ◽

Keyword(s):

Hodgkin Lymphoma ◽

Low Dose ◽

Classical Hodgkin Lymphoma ◽

Resource Constrained

Download Full-text

Genetic Variants of Interleukin 10 (IL10) are Associated with Clinical Outcome and Tumor Microenvironment Composition of Classical Hodgkin Lymphoma (cHL)

Klinische Pädiatrie ◽

10.1055/s-0034-1371111 ◽

2014 ◽

Vol 226 (02) ◽

Author(s):

M Vera-Lozada ◽

M Barros ◽

A García Costa ◽

R Hassan

Keyword(s):

Tumor Microenvironment ◽

Clinical Outcome ◽

Hodgkin Lymphoma ◽

Genetic Variants ◽

Interleukin 10 ◽

Classical Hodgkin Lymphoma

Download Full-text

M2 Macrophages but not M1 Macrophages Are Associated with Worst Outcome in Classical Hodgkin Lymphoma

Klinische Pädiatrie ◽

10.1055/s-0034-1371109 ◽

2014 ◽

Vol 226 (02) ◽

Author(s):

M Barros ◽

P Segges ◽

G Vera-Lozada ◽

R Hassan ◽

G Niedobitek

Keyword(s):

Hodgkin Lymphoma ◽

M2 Macrophages ◽

Classical Hodgkin Lymphoma ◽

Download Full-text

Beta-2 Microglobulin (B2 M) Genomic Alterations and Absent Protein Expression in Pediatric and Adolescent Classical Hodgkin Lymphoma

Klinische Pädiatrie ◽

10.1055/s-0034-1371104 ◽

2014 ◽

Vol 226 (02) ◽

Author(s):

L Giulino-Roth ◽

J Reichel ◽

J Teruya-Feldstein ◽

W Tam ◽

Y Tam ◽

...

Keyword(s):

Protein Expression ◽

Hodgkin Lymphoma ◽

Classical Hodgkin Lymphoma ◽

Genomic Alterations ◽

Beta 2 ◽

Beta 2 Microglobulin

Download Full-text

High response rate to combined chemotherapy avoiding radiotherapy in children and adolescents with classical Hodgkin lymphoma. Preliminary results of GALOP LH 2017 Protocol

10.1055/s-0040-1701859 ◽

2020 ◽

Author(s):

EM Alfaro ◽

M Schelotto ◽

M Guitter ◽

C Sanchez ◽

L Peruzzo ◽

...

Keyword(s):

Children And Adolescents ◽

Hodgkin Lymphoma ◽

Response Rate ◽

High Response Rate ◽

High Response ◽

Combined Chemotherapy ◽

Classical Hodgkin Lymphoma ◽

Preliminary Results

Download Full-text

Faculty Opinions recommendation of Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727454561.793552722 ◽

2018 ◽

Author(s):

Boris Böll

Keyword(s):

Hodgkin Lymphoma ◽

Phase Ii ◽

Phase Ii Study ◽

Selective Inhibitor ◽

Classical Hodgkin Lymphoma

Download Full-text